Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Preclinical characterization of mobocertinib highlights the putative therapeutic window of this novel EGFR inhibitor to EGFR exon 20 insertion mutations

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.09.28.317560Source: DataRank Database

Preclinical characterization of mobocertinib highlights the putative therapeutic window of this novel EGFR inhibitor to EGFR exon 20 insertion mutations is a research paper published in bioRxiv (Cold Spring Harbor Laboratory) (2020). On theSindex it has a DataRank of 0. It has been cited 20 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access20 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)OA: greenTopics (28)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (4)

Ikei S. Kobayashi,Susumu Kobayashi ORCID,Daniel B. Costa ORCID,Pedro Eduardo Nascimento Silva Vasconcelos ORCID

Live enrichment

PubMed:23304386 OpenAlex:https://openalex.org/W3089272461

National Institutes of Health

Grant: 5R37CA218707-07

Unmet needs for specific subsets of EGFR mutated lung cancer

National Institutes of Health

Grant: 5R01CA240257-02

Role of KAT5 in lung cancer

greenLicense: CC BY NC ND

repositoryhttps://www.biorxiv.org/content/biorxiv/early/2020/09/28/2020.09.28.317560.full.pdf

publisherhttps://syndication.highwire.org/content/doi/10.1101/2020.09.28.317560

repositoryhttps://doi.org/10.1101/2020.09.28.317560

https://doi.org/10.1016/j.jtocrr.2020.100105

Fields of Study

Lung Cancer Treatments and MutationsPI3K/AKT/mTOR signaling in cancerChronic Lymphocytic Leukemia Research0301 basic medicine03 medical and health sciences0302 clinical medicine

Keywords

OsimertinibEpidermal growth factor receptorExonEGFR inhibitorsCancer researchMutantGefitinibMutationMedicineBiologyErlotinibCancerGeneGeneticsMobocertinibC797SBrief ReportEGFR exon 20 insertionNeoplasms. Tumors. Oncology. Including cancer and carcinogensLung cancerERBB2RC254-282

Sustainable Development Goals

SDG 3: 3. Good health